



Five Prime Therapeutics Announces Timing of Its First Quarter 2020 Results Conference Call

April 30, 2020

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr. 30, 2020-- [Five Prime Therapeutics, Inc.](#) (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its first quarter 2020 operational and financial results on Thursday, May 7, 2020 after the U.S. financial markets close. Five Prime will also host a conference call and live audio webcast on Thursday, May 7, 2020 at 4:30 p.m. (ET) / 1:30 p.m. (PT) to provide a general business update and discuss the company's financial results.

The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (253) 237-1188 (domestic) or (877) 878-2269 (international) and refer to conference ID: 5376706.

The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc. develops innovative protein therapeutics to improve the lives of patients with cancer. Five Prime's product candidates have innovative mechanisms of action and address patient populations in need of better cancer therapies. The company focuses on developing immuno-oncology and targeted cancer therapies paired with companion diagnostics to identify patients who are most likely to benefit from treatment with Five Prime's product candidates. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

Source: Five Prime Therapeutics, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200430005897/en/): <https://www.businesswire.com/news/home/20200430005897/en/>

Media and Investor Contact

Martin Forrest
VP, Investor Relations & Corporate Communications
Five Prime Therapeutics, Inc.
415-365-5625
martin.forrest@fiveprime.com

Source: Five Prime Therapeutics, Inc.